1. Home
  2. NXPL vs IGC Comparison

NXPL vs IGC Comparison

Compare NXPL & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXPL
  • IGC
  • Stock Information
  • Founded
  • NXPL 1997
  • IGC 2005
  • Country
  • NXPL United States
  • IGC United States
  • Employees
  • NXPL N/A
  • IGC N/A
  • Industry
  • NXPL Telecommunications Equipment
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXPL Telecommunications
  • IGC Health Care
  • Exchange
  • NXPL Nasdaq
  • IGC Nasdaq
  • Market Cap
  • NXPL 17.9M
  • IGC 20.2M
  • IPO Year
  • NXPL N/A
  • IGC N/A
  • Fundamental
  • Price
  • NXPL $0.75
  • IGC $0.31
  • Analyst Decision
  • NXPL
  • IGC Strong Buy
  • Analyst Count
  • NXPL 0
  • IGC 2
  • Target Price
  • NXPL N/A
  • IGC $3.88
  • AVG Volume (30 Days)
  • NXPL 27.9K
  • IGC 219.7K
  • Earning Date
  • NXPL 08-13-2025
  • IGC 08-07-2025
  • Dividend Yield
  • NXPL N/A
  • IGC N/A
  • EPS Growth
  • NXPL N/A
  • IGC N/A
  • EPS
  • NXPL N/A
  • IGC N/A
  • Revenue
  • NXPL $62,515,000.00
  • IGC $1,236,000.00
  • Revenue This Year
  • NXPL N/A
  • IGC N/A
  • Revenue Next Year
  • NXPL N/A
  • IGC $16.45
  • P/E Ratio
  • NXPL N/A
  • IGC N/A
  • Revenue Growth
  • NXPL 19.36
  • IGC 1.65
  • 52 Week Low
  • NXPL $0.43
  • IGC $0.25
  • 52 Week High
  • NXPL $2.30
  • IGC $0.50
  • Technical
  • Relative Strength Index (RSI)
  • NXPL 59.43
  • IGC 52.79
  • Support Level
  • NXPL $0.65
  • IGC $0.30
  • Resistance Level
  • NXPL $0.77
  • IGC $0.32
  • Average True Range (ATR)
  • NXPL 0.06
  • IGC 0.01
  • MACD
  • NXPL 0.00
  • IGC 0.00
  • Stochastic Oscillator
  • NXPL 73.33
  • IGC 33.33

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: